Bristol-Myers Squibb Receives Positive Decision from NIH for YERVOY
Squibb Company (NYSE: BMY) is pleased to announce that today the National
Institute of Health and Clinical Excellence (NICE) has
decided to recommend YERVOY® (ipilimumab), which is
approved in the European Union for the treatment of previously-treated
metastatic (advanced) melanoma, within the Final Appraisal Determination
(FAD). This important decision will enable eligible patients in England
and Wales to routinely access treatment with YERVOY through the National
Health Services (NHS).
“Today's decision is very welcome news and marks a major milestone in
the treatment of advanced melanoma,” said Dr. Paul Lorigan, Senior
Lecturer in Medical Oncology, the Christie NHS Foundation Trust.
“Ipilimumab's potential to provide a long-term survival benefit